We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist

William E. Klunk, MD, PhD
Arch Neurol. 2008;65(10):1281-1283. doi:10.1001/archneur.65.10.1281.
Text Size: A A A
Published online


Amyloid imaging with the positron emission tomography (PET) ligand Pittsburgh Compound B (PiB) has spread to many centers around the world since the presentation of its first human studies performed in Uppsala, Sweden, in 2002.1 At the time of this writing, there are at least 17 sites in North America, 9 in Japan, 8 in Europe, 3 in Korea, and 1 in Australia that have successfully used PiB PET in thousands of subjects. Amyloid imaging with PiB has become an integral part of the Alzheimer's Disease Neuroimaging Initiative in North America and equivalent studies in Japan and Australia. The relatively rapid worldwide acceptance of this new technology lies partly in the potential utility of amyloid imaging for the following: (1) early (perhaps presymptomatic) diagnosis; (2) the development of antiamyloid therapies; and (3) deepening our understanding of the pathogenesis of Alzheimer disease (AD). Another reason for the rapid dissemination of PiB imaging may have been the body of preclinical work supporting the concept that PiB retention accurately reflects the deposition of fibrillar β-amyloid (Aβ) deposits in the brain.24 That, along with the fact that the pattern of PiB retention in humans5 matched the expected pattern of amyloid deposition deduced from the study of postmortem brain tissue,68 built confidence in the validity of amyloid imaging and encouraged the proliferation of this technology. Confidence in the relationship between PiB retention and amyloid content has been further bolstered by 2 postmortem studies that correlated in vivo PiB retention to postmortem measures of amyloid deposition. The first of these focused on a case with a clinical diagnosis of dementia with Lewy bodies and extensive cerebral amyloid angiopathy.9 The second was a case that showed the typical clinical symptoms of AD and classic AD pathological findings at autopsy.10 These postmortem studies showed that the amount and location of in vivo PiB retention in these 2 cases corresponded very well to the amount and location of Aβ deposits present after death.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

10 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Clarifying Your Question

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Three Examples of Question Clarification